Takeshi Yokoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Yokoo has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- Diego Hernando
Radiology University of Wisconsin‐Madison Madison Wisconsin USA
7 shared publications - Ivan Pedrosa
Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, USA
7 shared publications - Scott Brian Reeder
Department of Radiology University of Wisconsin–Madison Madison Wisconsin USA
7 shared publications - Claude B. Sirlin
Liver Imaging Group, Department of Radiology, University of California San Diego, La Jolla, CA, USA
6 shared publications Ivan Pedrosa
Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9085, USA
6 shared publications- Gaurav Khatri
The University of Texas Southwestern Medical Center, Dallas, USA
5 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Elsevier in American Journal of Medicine Open
Regional Body Tissue Distribution and Sleep Deficiency in Midlife and Older Adults
- 5 November 2026
- Published by Elsevier in American Journal of Medicine Open
Open AccessRegional Body Tissue Distribution and Sleep Deficiency in Midlife and Older Adults
- Open Access
- 20 May 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 64 (2) , 482-492
Cross‐Vendor Validation of Proton Density Fat Fraction and T 1 Mapping Using a Combined Proton Density Fat Fraction— T1 Phantom
Background: In chronic liver disease, fat and fibroinflammatory changes often coexist. However, their biomarkers, proton density fat fraction (PDFF) and T 1 , are typically assessed separately. Their reproducibility under mutual confounding remains unclear. Purpose: To assess multicenter, multi‐vendor reproducibility of confounder‐corrected chemical shift‐encoded (CSE)‐MRI‐based PDFF mapping and MOLLI‐based T 1 mapping using a combined PDFF‐T 1 phantom. Study Type: Prospective phantom study. Phantom: Commercial PDFF‐T 1 Phantom (Model 725) with varying PDFF (0%–30%) and T 1 (200–1400 ms) values. Field Strength/Sequence: 1.5 T and 3 T multi‐echo, three‐dimensional spoiled‐gradient‐echo (SGRE) sequence for PDFF mapping, and MOLLI sequence (5(3)3 acquisition scheme) using two‐dimensional SGRE readouts for T 1 mapping across four centers and vendors. Assessment: PDFF and T 1 maps were acquired using standardized protocols. PDFF maps were reconstructed locally, while T 1 maps were generated using a centralized algorithm. All maps were quantitatively analyzed by a single radiologist using standardized region‐of‐interest placement. Phantom temporal stability was assessed at one center across five sessions over 9 months (baseline, retest, 1 week, 6 and 9 months). Statistical Tests: Intraclass correlation coefficients (ICC), reproducibility coefficients (RDC), and linear regression analysis were used. A p value < 0.05 was considered statistically significant. Results: PDFF showed overall excellent reproducibility (ICC = 0.987, RDC = 3.7%), with increased variability at higher T 1 values (RDC up to 7.9% at T 1 = 1400 ms). T 1 mapping showed good reproducibility in the absence of fat (RDC 16–161 ms at PDFF = 0%), but moderate to poor reproducibility in the presence of fat, with RDC increasing up to 1553 ms at PDFF 30%. Temporal stability was excellent ICC ≥ 0.998 for both PDFF and T 1 , and RDC of 1.1%–1.3% for PDFF and 52–57 ms for T 1 . Data Conclusion: This phantom study demonstrated high reproducibility of PDFF, whereas T 1 reproducibility deteriorated at higher fat and T 1 levels, underscoring the need for fat‐corrected T 1 mapping for reliable assessment of fibroinflammatory changes. Evidence Level: N/A. Technical Efficacy: Stage 1.
- 20 May 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 64 (2) , 482-492
Open AccessCross‐Vendor Validation of Proton Density Fat Fraction and T 1 Mapping Using a Combined Proton Density Fat Fraction— T1 Phantom
Background: In chronic liver disease, fat and fibroinflammatory changes often coexist. However, their biomarkers, proton density fat fraction (PDFF) and T 1 , are typically assessed separately. Their reproducibility under mutual confounding remains unclear. Purpose: To assess multicenter, multi‐vendor reproducibility of confounder‐corrected chemical shift‐encoded (CSE)‐MRI‐based PDFF mapping and MOLLI‐based T 1 mapping using a combined PDFF‐T 1 phantom. Study Type: Prospective phantom study. Phantom: Commercial PDFF‐T 1 Phantom (Model 725) with varying PDFF (0%–30%) and T 1 (200–1400 ms) values. Field Strength/Sequence: 1.5 T and 3 T multi‐echo, three‐dimensional spoiled‐gradient‐echo (SGRE) sequence for PDFF mapping, and MOLLI sequence (5(3)3 acquisition scheme) using two‐dimensional SGRE readouts for T 1 mapping across four centers and vendors. Assessment: PDFF and T 1 maps were acquired using standardized protocols. PDFF maps were reconstructed locally, while T 1 maps were generated using a centralized algorithm. All maps were quantitatively analyzed by a single radiologist using standardized region‐of‐interest placement. Phantom temporal stability was assessed at one center across five sessions over 9 months (baseline, retest, 1 week, 6 and 9 months). Statistical Tests: Intraclass correlation coefficients (ICC), reproducibility coefficients (RDC), and linear regression analysis were used. A p value < 0.05 was considered statistically significant. Results: PDFF showed overall excellent reproducibility (ICC = 0.987, RDC = 3.7%), with increased variability at higher T 1 values (RDC up to 7.9% at T 1 = 1400 ms). T 1 mapping showed good reproducibility in the absence of fat (RDC 16–161 ms at PDFF = 0%), but moderate to poor reproducibility in the presence of fat, with RDC increasing up to 1553 ms at PDFF 30%. Temporal stability was excellent ICC ≥ 0.998 for both PDFF and T 1 , and RDC of 1.1%–1.3% for PDFF and 52–57 ms for T 1 . Data Conclusion: This phantom study demonstrated high reproducibility of PDFF, whereas T 1 reproducibility deteriorated at higher fat and T 1 levels, underscoring the need for fat‐corrected T 1 mapping for reliable assessment of fibroinflammatory changes. Evidence Level: N/A. Technical Efficacy: Stage 1.
- 23 January 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (4) , 1282-1292
Examining Disparities in Patient Motion During MRI
- 23 January 2026
- Published by Elsevier in Academic Radiology
- Vol. 33 (4) , 1282-1292
Examining Disparities in Patient Motion During MRI
- Open Access
- 18 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (3) , 800-811
Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom
Background: Fat and iron deposition confound measurements of R2* and proton density fat fraction (PDFF), respectively, yet their combined impact on reproducibility is poorly understood.Purpose: To evaluate the multi‐center, multi‐vendor reproducibility of PDFF and R2* quantification using a PDFF‐R2* phantom.Study Type: Prospective multi‐center, phantom study.Phantom: Commercial PDFF‐R2* phantom with simultaneously controlled combination of PDFF (0%–30%) and R2* (50–600 s−1) values.Field Strength/Sequence: 1.5‐T and 3‐T, three‐dimensional (3D) multi‐echo, spoiled‐gradient‐echo sequences, in four different centers, each with a different vendor.Assessment: Two acquisition protocols were used, optimized for moderate R2* (Protocol 1) and high R2* (Protocol 2), respectively. The phantom was imaged multiple times at one of the centers to assess its stability.Statistical Tests: Intraclass correlation coefficient (ICC), linear regression analysis, reproducibility coefficient (RDC) and repeatability coefficient (RC).Results: Excellent agreement was observed for PDFF measurements between centers, vendors, field strengths, and protocols (ICC = 0.97). Stratified by protocol, excellent agreement was observed, with ICC = 0.96 (RDC = 6.2%) for Protocol 1 and ICC = 0.99 (RDC = 3.8%) for Protocol 2. Increased variability in PDFF measurements was observed with increasing PDFF and especially with higher R2*. Excellent agreement was observed for R2* between centers, vendors, field strengths, and protocols (ICC = 0.99). Stratified by protocol, strong agreement was observed, with ICC = 0.988 (RDC = 66.7 s−1) for Protocol 1 and ICC = 0.99 (RDC = 57.7 s−1) for Protocol 2. Higher variability in R2* measurements was observed in vials with higher PDFF or R2*. Stability tests demonstrated an ICC = 1.0 for PDFF and R2*, and RC of 0.4% for PDFF and 12 s−1 for R2*.Data Conclusion: Excellent PDFF and R2* reproducibility was observed across centers, vendors, field strengths, and acquisition protocols. Reproducibility decreased slightly with increasing PDFF and R2*, especially for PDFF measurements in vials with high R2*.Evidence Level: N/A.Technical Efficacy: Stage 1.
- 18 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (3) , 800-811
Open AccessMulti‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom
Background: Fat and iron deposition confound measurements of R2* and proton density fat fraction (PDFF), respectively, yet their combined impact on reproducibility is poorly understood.Purpose: To evaluate the multi‐center, multi‐vendor reproducibility of PDFF and R2* quantification using a PDFF‐R2* phantom.Study Type: Prospective multi‐center, phantom study.Phantom: Commercial PDFF‐R2* phantom with simultaneously controlled combination of PDFF (0%–30%) and R2* (50–600 s−1) values.Field Strength/Sequence: 1.5‐T and 3‐T, three‐dimensional (3D) multi‐echo, spoiled‐gradient‐echo sequences, in four different centers, each with a different vendor.Assessment: Two acquisition protocols were used, optimized for moderate R2* (Protocol 1) and high R2* (Protocol 2), respectively. The phantom was imaged multiple times at one of the centers to assess its stability.Statistical Tests: Intraclass correlation coefficient (ICC), linear regression analysis, reproducibility coefficient (RDC) and repeatability coefficient (RC).Results: Excellent agreement was observed for PDFF measurements between centers, vendors, field strengths, and protocols (ICC = 0.97). Stratified by protocol, excellent agreement was observed, with ICC = 0.96 (RDC = 6.2%) for Protocol 1 and ICC = 0.99 (RDC = 3.8%) for Protocol 2. Increased variability in PDFF measurements was observed with increasing PDFF and especially with higher R2*. Excellent agreement was observed for R2* between centers, vendors, field strengths, and protocols (ICC = 0.99). Stratified by protocol, strong agreement was observed, with ICC = 0.988 (RDC = 66.7 s−1) for Protocol 1 and ICC = 0.99 (RDC = 57.7 s−1) for Protocol 2. Higher variability in R2* measurements was observed in vials with higher PDFF or R2*. Stability tests demonstrated an ICC = 1.0 for PDFF and R2*, and RC of 0.4% for PDFF and 12 s−1 for R2*.Data Conclusion: Excellent PDFF and R2* reproducibility was observed across centers, vendors, field strengths, and acquisition protocols. Reproducibility decreased slightly with increasing PDFF and R2*, especially for PDFF measurements in vials with high R2*.Evidence Level: N/A.Technical Efficacy: Stage 1.
- 13 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3617-e3625
Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy
Context: Patients with familial partial lipodystrophy (FPLD) have increased risk of hepatic steatosis and its complications, for which there is no approved therapy. Objective: This work aimed to investigate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor agonist, for reducing hepatic steatosis in patients with FPLD. Methods: A randomized, double-blind, placebo-controlled, crossover trial was conducted at an academic referral center. Ten women (age 19-60 years) with the Dunnigan variety of FPLD (FPLD2), harboring pathogenic heterozygous variants in the lamin A/C gene and hepatic steatosis (liver fat >5.6% by proton-density fat fraction mapping by magnetic resonance imaging), were included. Intervention included OCA 25 mg daily vs matched placebo for 4 months each with a 4-month washout period in between. The primary end point variable was liver fat. Secondary end point variables were serum triglycerides (TGs) and transaminase levels. Results: All patients completed the trial. OCA therapy caused significant (39.6%) reduction in liver fat as compared to placebo (median liver fat [minimum-maximum]; 6.4% [2.4%-18.0%] vs 10.6% [3.4%-29.3%], respectively; P value for treatment × month interaction = .03). There were no significant differences in serum TGs or transaminase levels during OCA and placebo therapy. Overall, OCA was well tolerated except for itching in 4 patients compared to 2 on placebo. OCA, as compared to placebo, caused 24% increase in serum low-density lipoprotein cholesterol (mean 129 mg/dL vs 104 mg/dL, respectively; P = .0016). Conclusion: OCA is safe and effective in lowering hepatic TG levels in patients with FPLD2.
- 13 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3617-e3625
Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy
Context: Patients with familial partial lipodystrophy (FPLD) have increased risk of hepatic steatosis and its complications, for which there is no approved therapy. Objective: This work aimed to investigate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor agonist, for reducing hepatic steatosis in patients with FPLD. Methods: A randomized, double-blind, placebo-controlled, crossover trial was conducted at an academic referral center. Ten women (age 19-60 years) with the Dunnigan variety of FPLD (FPLD2), harboring pathogenic heterozygous variants in the lamin A/C gene and hepatic steatosis (liver fat >5.6% by proton-density fat fraction mapping by magnetic resonance imaging), were included. Intervention included OCA 25 mg daily vs matched placebo for 4 months each with a 4-month washout period in between. The primary end point variable was liver fat. Secondary end point variables were serum triglycerides (TGs) and transaminase levels. Results: All patients completed the trial. OCA therapy caused significant (39.6%) reduction in liver fat as compared to placebo (median liver fat [minimum-maximum]; 6.4% [2.4%-18.0%] vs 10.6% [3.4%-29.3%], respectively; P value for treatment × month interaction = .03). There were no significant differences in serum TGs or transaminase levels during OCA and placebo therapy. Overall, OCA was well tolerated except for itching in 4 patients compared to 2 on placebo. OCA, as compared to placebo, caused 24% increase in serum low-density lipoprotein cholesterol (mean 129 mg/dL vs 104 mg/dL, respectively; P = .0016). Conclusion: OCA is safe and effective in lowering hepatic TG levels in patients with FPLD2.
- 14 February 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 185, 112001
An algorithmic approach to MR characterization of focal liver lesions in adults without cirrhosis
- 14 February 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 185, 112001
An algorithmic approach to MR characterization of focal liver lesions in adults without cirrhosis
- 24 December 2024
- Published by Elsevier in Clinical Imaging
- Vol. 118, 110394
Updates on the MR safety guidelines – Essentials for radiologists
- 24 December 2024
- Published by Elsevier in Clinical Imaging
- Vol. 118, 110394
Updates on the MR safety guidelines – Essentials for radiologists
- 30 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2502-2511
Performing liver imaging at a high level: quality and adequacy in LI-RADS
Imaging is critical to HCC management, including surveillance, diagnosis, staging, and treatment response assessment, which requires it be performed consistently at a high level. The Liver Imaging Reporting and Data System (LI-RADS) was developed to standardize the acquisition, interpretation, and reporting of liver imaging, but until now, has not addressed the essential component of exam quality and adequacy. In this manuscript, we discuss the concepts of quality and adequacy and their clinical significance in the setting of HCC diagnostic imaging and treatment response assessment. We describe prior and current efforts to improve image quality and adequacy. We review common sources of image degradation that need to be addressed and the rationale behind LI-RADS technical recommendations. Finally, we offer a glimpse into preliminary efforts to develop an adequacy scoring system and make a call to action for all stakeholders to contribute to this important goal.
- 30 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2502-2511
Performing liver imaging at a high level: quality and adequacy in LI-RADS
Imaging is critical to HCC management, including surveillance, diagnosis, staging, and treatment response assessment, which requires it be performed consistently at a high level. The Liver Imaging Reporting and Data System (LI-RADS) was developed to standardize the acquisition, interpretation, and reporting of liver imaging, but until now, has not addressed the essential component of exam quality and adequacy. In this manuscript, we discuss the concepts of quality and adequacy and their clinical significance in the setting of HCC diagnostic imaging and treatment response assessment. We describe prior and current efforts to improve image quality and adequacy. We review common sources of image degradation that need to be addressed and the rationale behind LI-RADS technical recommendations. Finally, we offer a glimpse into preliminary efforts to develop an adequacy scoring system and make a call to action for all stakeholders to contribute to this important goal.
- 15 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (5) , 2097-2109
Exam quality of ultrasound and dynamic contrast-enhanced abbreviated MRI and impact on early-stage HCC detection
Purpose MRI is a potential alternative to ultrasound for hepatocellular carcinoma (HCC) detection. We evaluated the impact of ultrasound and dynamic abbreviated MRI (AMRI) exam quality on early-stage HCC detection. Methods We conducted a multicenter case-control study among patients with cirrhosis (cases with early-stage HCC per Milan Criteria; controls without HCC) who underwent both a liver ultrasound and dynamic contrast-enhanced (DCE) AMRI within 6 months in 2012–2019. Two radiologists performed independent, blinded interpretations of both exams for HCC detection and scored exam quality as no/mild, moderate, or severe limitations. Associations between exam quality, patient characteristics, and HCC detection were assessed by odds ratios (OR). Results Of 216 cases and 432 controls, severe limitations were reported in 7% and 8% of ultrasounds and DCE-AMRIs, respectively. Severe limitations at ultrasound were associated with obesity (OR 2.08, 95%CI [1.32–3.32]) and metabolic dysfunction-associated steatotic liver disease (MASLD) (OR 1.98 [1.12–3.44]) but not for DCE-AMRI. Decompensated cirrhosis (Child-Pugh C) was associated with severe limitations for both ultrasound (OR 2.54 [1.37–4.58]) and DCE-AMRI (OR 3.96 [2.36–6.58]). Compared to exams with no/mild limitations, exams with severe limitations had lower sensitivity for ultrasound (79.6% vs. 21.7%, P < 0.001) and AMRI (86.1% vs. 50.0%, P = 0.001). In patients in whom ultrasound was severely limited, DCE-AMRI had significantly higher odds of early-stage HCC detection than ultrasound (OR 8.23 [1.25–54.02]). Conclusions HCC detection by DCE-AMRI may be preferred in patients with severe limitations at ultrasound due to obesity and MASLD. Both modalities remain limited for patients with decompensated cirrhosis, for whom alternative strategies may be needed.
- 15 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (5) , 2097-2109
Exam quality of ultrasound and dynamic contrast-enhanced abbreviated MRI and impact on early-stage HCC detection
Purpose MRI is a potential alternative to ultrasound for hepatocellular carcinoma (HCC) detection. We evaluated the impact of ultrasound and dynamic abbreviated MRI (AMRI) exam quality on early-stage HCC detection. Methods We conducted a multicenter case-control study among patients with cirrhosis (cases with early-stage HCC per Milan Criteria; controls without HCC) who underwent both a liver ultrasound and dynamic contrast-enhanced (DCE) AMRI within 6 months in 2012–2019. Two radiologists performed independent, blinded interpretations of both exams for HCC detection and scored exam quality as no/mild, moderate, or severe limitations. Associations between exam quality, patient characteristics, and HCC detection were assessed by odds ratios (OR). Results Of 216 cases and 432 controls, severe limitations were reported in 7% and 8% of ultrasounds and DCE-AMRIs, respectively. Severe limitations at ultrasound were associated with obesity (OR 2.08, 95%CI [1.32–3.32]) and metabolic dysfunction-associated steatotic liver disease (MASLD) (OR 1.98 [1.12–3.44]) but not for DCE-AMRI. Decompensated cirrhosis (Child-Pugh C) was associated with severe limitations for both ultrasound (OR 2.54 [1.37–4.58]) and DCE-AMRI (OR 3.96 [2.36–6.58]). Compared to exams with no/mild limitations, exams with severe limitations had lower sensitivity for ultrasound (79.6% vs. 21.7%, P < 0.001) and AMRI (86.1% vs. 50.0%, P = 0.001). In patients in whom ultrasound was severely limited, DCE-AMRI had significantly higher odds of early-stage HCC detection than ultrasound (OR 8.23 [1.25–54.02]). Conclusions HCC detection by DCE-AMRI may be preferred in patients with severe limitations at ultrasound due to obesity and MASLD. Both modalities remain limited for patients with decompensated cirrhosis, for whom alternative strategies may be needed.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (8) , e230173
T1-weighted Motion Mitigation in Abdominal MRI: Technical Principles, Clinical Applications, Current Limitations, and Future Prospects
T1-weighted (T1W) pulse sequences are an indispensable component of clinical protocols in abdominal MRI but usually require multiple breath holds (BHs) during the examination, which not all patients can sustain. Patient motion can affect the quality of T1W imaging so that key diagnostic information, such as intrinsic signal intensity and contrast enhancement image patterns, cannot be determined. Patient motion also has a negative impact on examination efficiency, as multiple acquisition attempts prolong the duration of the examination and often remain noncontributory. Techniques for mitigation of motion-related artifacts at T1W imaging include multiple arterial acquisitions within one BH; free breathing with respiratory gating or respiratory triggering; and radial imaging acquisition techniques, such as golden-angle radial k-space acquisition (stack-of-stars). While each of these techniques has inherent strengths and limitations, the selection of a specific motion-mitigation technique is based on several factors, including the clinical task under investigation, downstream technical ramifications, patient condition, and user preference. The authors review the technical principles of free-breathing motion mitigation techniques in abdominal MRI with T1W sequences, offer an overview of the established clinical applications, and outline the existing limitations of these techniques. In addition, practical guidance for abdominal MRI protocol strategies commonly encountered in clinical scenarios involving patients with limited BH abilities is rendered. Future prospects of free-breathing T1W imaging in abdominal MRI are also discussed. ©RSNA, 2024 See the invited commentary by Fraum and An in this issue.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (8) , e230173
T1-weighted Motion Mitigation in Abdominal MRI: Technical Principles, Clinical Applications, Current Limitations, and Future Prospects
T1-weighted (T1W) pulse sequences are an indispensable component of clinical protocols in abdominal MRI but usually require multiple breath holds (BHs) during the examination, which not all patients can sustain. Patient motion can affect the quality of T1W imaging so that key diagnostic information, such as intrinsic signal intensity and contrast enhancement image patterns, cannot be determined. Patient motion also has a negative impact on examination efficiency, as multiple acquisition attempts prolong the duration of the examination and often remain noncontributory. Techniques for mitigation of motion-related artifacts at T1W imaging include multiple arterial acquisitions within one BH; free breathing with respiratory gating or respiratory triggering; and radial imaging acquisition techniques, such as golden-angle radial k-space acquisition (stack-of-stars). While each of these techniques has inherent strengths and limitations, the selection of a specific motion-mitigation technique is based on several factors, including the clinical task under investigation, downstream technical ramifications, patient condition, and user preference. The authors review the technical principles of free-breathing motion mitigation techniques in abdominal MRI with T1W sequences, offer an overview of the established clinical applications, and outline the existing limitations of these techniques. In addition, practical guidance for abdominal MRI protocol strategies commonly encountered in clinical scenarios involving patients with limited BH abilities is rendered. Future prospects of free-breathing T1W imaging in abdominal MRI are also discussed. ©RSNA, 2024 See the invited commentary by Fraum and An in this issue.